Shares of Delcath Systems DCTH were unchanged after the company reported Q1 results.
Quarterly Results
Earnings per share rose 99.04% over the past year to ($1.04), which missed the estimate of ($0.98).
Revenue of $388,000 higher by 31.97% year over year, which missed the estimate of $400,000.
Guidance
Delcath Systems hasn't issued any earnings guidance for the time being.
Delcath Systems hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: May 11, 2021
Time: 08:30 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2475/41204
Recent Stock Performance
Company's 52-week high was at $25.18
52-week low: $7.15
Price action over last quarter: down 16.24%
Company Profile
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
